Phathom Pharmaceuticals Inc. (PHAT) Prices 2.25M Share Common Offering at $42/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Phathom Pharmaceuticals Inc. (PHAT) Announces Proposed 2.5M Common Share Offering
December 15, 2020 4:02 PM ESTPhathom Pharmaceuticals, Inc. (NASDAQ: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other conditions, 2,250,000 shares of its common stock in an underwritten public... More
Phathom Pharmaceuticals (PHAT) PT Raised to $55 at Needham & Company
December 15, 2020 8:42 AM ESTNeedham & Company analyst Alan Carr raised the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $55.00 (from $45.00) while maintaining a Buy rating.
The analyst commented, "Phathom hosted a virtual R&D event and announced plans to initiate Phase 2 testing of vonoprazan in... More
